SCHEMBL4869815

SCHEMBL4869815

CC(C)(C)[Si](C)(C)OC1CCCN(C(=O)Nc2ccc(O)cc2)c2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.43
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 2/20 0.40
NFKB1 P19838 2/20 0.40
RAB9A P51151 2/20 0.40
NFKB2 Q00653 2/20 0.40
RELA Q04206 2/20 0.40
PKM P14618 1/20 0.40
MAOB P27338 1/20 0.40
AVPR2 P30518 4/20 0.39
AVPR1A P37288 4/20 0.39
TP53 P04637 2/20 0.39
LMNA P02545 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
ABCB11 O95342 1/20 0.37
HTR1A P08908 1/20 0.37
CHRM1 P11229 1/20 0.37
OXTR P30559 1/20 0.37
SLC6A4 P31645 1/20 0.37
ADRA1A P35348 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898349 0.93 NPC1 (0.44) MAPTSMN1; SMN2NPC1NFKB1RAB9A
SCHEMBL4863128 0.88 MAPT (0.47) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL4861824 0.79 MAPT (0.48) MAPTSMN1; SMN2NPC1NFKB1RAB9A
SCHEMBL4867516 0.78 AVPR2 (0.56) MAPTSMN1; SMN2NPC1NFKB1RAB9A
SCHEMBL4870743 0.77 MAPT (0.46) MAPTSMN1; SMN2NPC1NFKB1RAB9A
SCHEMBL4870689 0.74 NPC1 (0.50) MAPTSMN1; SMN2NPC1NFKB1RAB9A
SCHEMBL4863835 0.72 MAPT (0.47) MAPTSMN1; SMN2NPC1NFKB1RAB9A
SCHEMBL2172195 0.71 NPC1 (0.50) SMN1; SMN2NPC1RAB9AGAA
SCHEMBL4867117 0.69 AVPR2 (0.56) MAPTSMN1; SMN2NPC1NFKB1RAB9A
SCHEMBL4870912 0.69 NPC1 (0.45) MAPTSMN1; SMN2NPC1NFKB1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 MAPT 3398/4885SMN1; SMN2 2595/4885NPC1 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.